Atropina al 0,01% e intervenciones de corrección óptica para ralentizar miopía infantil: Revisión Sistemática y Meta-análisis

Mareyke  Medina-Huayta; Edward  Chávez-Cruzado; Alan  Sánchez-Medina; Christopher  Valera-Chávez; José  Caballero; Julissa  Moya-Carranza

doi:10.35434/rcmhnaaa.2023.164.2083

Authors

Mareyke Medina-Huayta Escuela de Postgrado, Universidad Privada Antenor Orrego, La Libertad, Perú. https://orcid.org/0000-0002-3096-5212
Edward Chávez-Cruzado Facultad de Medicina Humana, Universidad Privada Antenor Orrego, Trujillo, Perú.
Alan Sánchez-Medina Facultad de Medicina Humana, Universidad Nacional de Trujillo, La Libertad, Perú.
Christopher Valera-Chávez Facultad de Medicina Humana, Universidad Nacional de Trujillo, La Libertad, Perú.
José Caballero Escuela de Postgrado, Universidad Privada Antenor Orrego, La Libertad, Perú.
Julissa Moya-Carranza Facultad de Medicina Humana, Universidad César Vallejo, La Libertad, Perú.

DOI:

https://doi.org/10.35434/rcmhnaaa.2023.164.2083

Keywords:

myopia, atropine 0,01%, lenses, children, systematic review

Abstract

Introduction: Vision is critical in all aspects and stages of life. Myopia is the second cause of visual impairment worldwide and the prevalence of childhood myopia is increasing at an alarming rate, so a single treatment intervention is not sufficient and interventions that slow its progression should be combined. Objective: to determine the effect of atropine in 0.01% ophthalmic drops combined with optical correction interventions to slow the progression of childhood myopia. Methodology: a systematic review of articles published in PubMed, Embase, Cochrane Library, Ovid MEDLINE, Scopus, Web of Science, ScienceDirect, and EBSCOhost up to March 28, 2022, was performed. Meta-analysis was performed with a random-effects model by subgroups of interest. Results: eight studies were selected (six randomized clinical trials, one nonrandomized trial, and one cohort study), including a total of 632 children with low and medium myopia who used orthokeratology or monofocal contact lenses and atropine 0.01% eye drops. The meta-analysis showed results in favor of combined treatment to slow axial elongation by -0.15 mm with a 95% confidence interval (-0.23 to -0.07), high risk of bias, and high heterogeneity (I2=94%). Conclusions: according to the available evidence, atropine in 0.01% eye drops combined with mono-focal lenses or orthokeratology contact lenses could reduce axial elongation in children with low and medium myopia; however, the results are heterogeneous and the risk of bias is high.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Mareyke Medina-Huayta, Escuela de Postgrado, Universidad Privada Antenor Orrego, La Libertad, Perú.

a. Magister en Investigación Clínica

b. Médico Pediatra

Edward Chávez-Cruzado, Facultad de Medicina Humana, Universidad Privada Antenor Orrego, Trujillo, Perú.

a. Médico Cirujano

Alan Sánchez-Medina, Facultad de Medicina Humana, Universidad Nacional de Trujillo, La Libertad, Perú.

a. Médico Anestesiólogo

Christopher Valera-Chávez, Facultad de Medicina Humana, Universidad Nacional de Trujillo, La Libertad, Perú.

a. Médico Cirujano

José Caballero, Escuela de Postgrado, Universidad Privada Antenor Orrego, La Libertad, Perú.

a. Doctor en Investigación Clínica y Traslacional

Julissa Moya-Carranza, Facultad de Medicina Humana, Universidad César Vallejo, La Libertad, Perú.

a. Médico Pediatra

References

Organización Mundial de la Salud. Informe mundial sobre la visión [Internet]. Ginebra: Organización Mundial de la Salud; 2020 [citado 14 de noviembre de 2021]. Disponible en: https://apps.who.int/iris/handle/10665/331423.

Pan CW, Dirani M, Cheng CY, Wong TY, Saw SM. The age-specific prevalence of myopia in Asia: a meta-analysis. Optom Vis Sci. 2015 Mar;92(3):258-266. doi: 10.1097/OPX.0000000000000516.

Rey-Rodríguez D, Álvarez C, Moreno-Montoya J. Prevalencia y factores asociados a miopía en jóvenes. Rev Mex Oftalmol. 2017;91(5):223-228. doi: 10.1016/j.mexoft.2016.06.007

Organización Mundial de la Salud. The impact of myopia and high myopia [Internet]. Ginebra: Organización Mundial de la Salud; 2015 [citado 14 de noviembre de 2021]. Disponible en: https://www.who.int/blindness/causes/MyopiaReportforWeb.pdf.

Li Y, Fu Y, Wang K, Liu Z, Shi X, Zhao M. Evaluating the myopia progression control efficacy of defocus incorporated multiple segments (DIMS) lenses and Apollo progressive addition spectacle lenses (PALs) in 6- to 12-year-old children: study protocol for a prospective, multicenter, randomized controlled trial. Trials. 2020;21(1):279. doi:10.1186/s13063-020-4095-8.

Matsuda K, Park K. Recent trend of increasing myopia can be traced to infancy. Med Hypotheses. 2019 Jul; 128:78-82. doi: 10.1016/j.mehy.2019.05.017.

Rudnicka AR, Kapetanakis VV, Wathern AK, Logan NS, Gilmartin B, Whincup PH, et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention. Br J Ophthalmol. 2016 Jul; 100(7):882-890. doi:10.1136/bjophthalmol-2015-307724.

Pérez-Flores I. Tratamiento médico de la miopía [Internet]. Acta Estrabológica. 2018; 2:79-94.

Pugazhendhi S, Ambati B, Hunter AA. Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia. Clin Ophthalmol. 2020; 14:853-873. doi:10.2147/OPTH.S241435.

Rey-Rodríguez D, Moreno-Montoya J, Álvarez-Peregrina C. Prevalencia de miopía en América: revisión sistemática y metaanálisis. Cienc Tecnol Salud Vis Ocul. 2021;19(1):49-58. doi: https://doi.org/10.19052/sv.vol19.iss1.6.

Jong M, Flitcroft DI. Report de Definición y Clasificación de la Miopía IMI [Internet]. The International Myopia Institute; 2019 [citado 14 de diciembre de 2021]. Disponible en: https://myopiainstitute.org/wp-content/uploads/2020/09/IMI-Defining-and-Classifying-Myopia-Report_SPANISH-FINALv2.pdf.

Errores de refracción en niños - UpToDate [Internet]. [citado 15 de noviembre de 2021]. Disponible en: https://www.uptodate.com/contents/refractive-errors-in-children?search=myopia&source=search_result&selectedTitle=2~139&usage_type=default&display_rank=2.

Lapido Polanco SI, Baldoquín Rodríguez W, López González M. La miopía degenerativa desde una perspectiva social. Rev Cuba Oftalmol [Internet]. 2014 [citado 2021 Dic 19]; 27(3):455-470. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762014000300012&lng=es.

Bermúdez JM, Arbolave D van E. Detección precoz de los trastornos de refracción. Pediatr Integral [Internet]. 2018 [citado 2021 Dic 19]; 22(1): 24–31. Disponible en: https://cdn.pediatriaintegral.es/wp-content/uploads/2018/xxii01/03/n1-024-031_JosepMares.pdf.

Castro LP, Hernández YN, Santos LRH, Perugorría AH. Características de los pacientes pediátricos con miopía por encima de 6 dioptrías. Rev Cuba Oftalmol [Internet]. 2019 [citado 2021 Dic 20]; 32(3):e797. Disponible en: http://www.revoftalmologia.sld.cu/index.php/oftalmologia/article/view/797.

Saw S-M, Matsumura S, Hoang QV. Prevention and Management of Myopia and Myopic Pathology. Invest Ophthalmol Vis Sci. 2019;60(2):488-499. doi: https://doi.org/10.1167/iovs.18-25221.

Correa Gamba LJ. Progresión de la miopía, durante seis meses, en una población de niños entre 6 y 10 años, pacientes de la Clínica de Optometría de la Universidad de La Salle. Cienc Tecnol Para Salud Vis Ocul. 2016;14(1):47-59. doi: https://doi.org/10.19052/sv.3648.

Jonas JB, Ang M, Cho P, Guggenheim JA, He MG, Jong M, et al. IMI Prevention of Myopia and Its Progression. Invest Ophthalmol Vis Sci. 2021;62(5):6. doi:10.1167/iovs.62.5.6.

Aguilar GG. Criterios clínicos para la corrección de la miopía [Internet]. Universidad Politécnica de Catalunya. 2019 [citado 2021 Dic 20]. Disponible en: https://upcommons.upc.edu/bitstream/handle/2117/190918/guillerma.galicia%20-%20TFG%20GUILLERMA%20GALICIA%20obert.pdf.

Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, et al. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 13 de enero de 2011;12. doi: 10.1002/14651858.CD004916.pub3.

Zhu Q, Liu Y, Tighe S, Zhu Y, Su X, Lu F, et al. Retardation of Myopia Progression by Multifocal Soft Contact Lenses. Int J Med Sci. 2019;16(2):198-202. doi:10.7150/ijms.30118.

Hyman L, Gwiazda J, Marsh-Tootle WL, Norton TT, Hussein M, COMET Group. The Correction of Myopia Evaluation Trial (COMET): design and general baseline characteristics. Control Clin Trials. 2001 Oct;22(5):573-592. doi: 10.1016/s0197-2456(01)00156-8.

Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Ophthalmology. 2016;123(4):697-708. doi: 10.1016/j.ophtha.2015.11.010.

Chua W-H, Balakrishnan V, Chan Y-H, Tong L, Ling Y, Quah B-L, et al. Atropine for the Treatment of Childhood Myopia. Ophthalmology. 2006;113(12):2285-2291. doi: 10.1016/j.ophtha.2006.05.062.

Chia A, Chua W-H, Cheung Y-B, Wong W-L, Lingham A, Fong A, et al. Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347-354. doi: 10.1016/j.ophtha.2011.07.031.

Lee SSY, Mackey DA, Lingham G, Crewe JM, Richards MD, Chen FK, et al. Western Australia Atropine for the Treatment of Myopia (WA-ATOM) study: Rationale, methodology and participant baseline characteristics. Clin Experiment Ophthalmol. 2020;48(5):569-579. https://doi.org/10.1111/ceo.13736.

Cooper J, Tkatchenko AV. A Review of Current Concepts of the Etiology and Treatment of Myopia. Eye Contact Lens. 2018;44(4):231-247. doi: 10.1097/ICL.0000000000000499.

Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;65(3):315-25. doi: 10.1007/s10384-021-00822-y.

Verzhanskaya TY. Primenenie atropina dlia lecheniia progressiruiushcheĭ miopii u deteĭ i podrostkov [Atropine use for progressive myopia in children and adolescents]. Vestn Oftalmol. 2017;133(3):89-98. Russian. doi: 10.17116/oftalma2017133389-98.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.

McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review ofElectronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40-6.https://doi.org/10.1016/j.jclinepi.2016.01.021.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile appforsystematic reviews. Systematic Reviews. 2016;5(1):1-10. https://doi.org/10.1186/s13643-016-0384-4.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898).

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; (355): i4919. doi: 10.1136/bmj.i4919.

Wells G.A., Wells G., Shea B., Shea B., O'Connell D., Peterson J. et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014.

Chen Z, Huang S, Zhou J, Xiaomei Q, Zhou X, Xue F. Adjunctive effect of orthokeratology and low dose atropine on axial elongation in fast-progressing myopic children-A preliminary retrospective study. Cont Lens Anterior Eye. 2019;42(4):439-442. doi: 10.1016/j.clae.2018.10.026.

Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, Kakehashi A. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Scientific Reports. 2020;10:12750. https://doi.org/10.1038/s41598-020-69710-8.

Wang Y, Yao J, Qu X. Atropine 0.01% for the Control of Myopia in Chinese Children: Effect on Accommodation Functions and Pupil Size. Clinical Study. Journal of Ophthalmology 2020. https://doi.org/10.1155/2020/7525180.

Vincent SJ, Tan Q, Ng ALK, Cheng GPM, Woo VCP, Cho P. Higher order aberrations and axial elongation in combined 0.01% atropine with orthokeratology for myopia control. Ophthalmic & Physiological Optics 2020;40:728–737. https://doi.org/10.1111/opo.12730.

Tan Q, Ng ALK, Choy NKQ, Cheng GPM, Woo VCP, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic & Physiological Optics 2020;40:557–566. https://doi.org/10.1111/opo.12722.

Tang W-T. Clinical observation of low-dose Atropine combined with orthokeratology in the treatment of myopia / 國際眼科雜誌(Guoji Yanke Zazhi). International Eye Science 2020;20(6):1044-1047. doi:10.3980/j.issn.1672-5123.2020.6.26.

Zhao Q, Hao Q. Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children. Int Ophthalmol. 2021; 41(3): 1011–1017. doi: 10.1007/s10792-020-01658-0.

Luo Y. Clinical observation of orthokeratology combined with 0.01% Atropine for controlling low to moderate myopia in adolescents / 國際眼科雜誌(Guoji Yanke Zazhi). 2021;21(1):47-52. doi:10.3980/j.issn.1672-5123.2021.1.09.

Wolffsohn JS, Kollbaum PS, Berntsen DA, Atchison DA, Benavente A, Bradley A. et al. IMI – Ensayos clínicos de control de la miopía e informe de instrumentación. Invertir. Oftalmol. Vis. ciencia 2019;60(3):M132-M160. https://doi.org/10.1167/iovs.18-25955.

Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Feb 16;2(2):CD014758. doi: 10.1002/14651858.CD014758.pub2. Accedida el 20 de marzo de 2023.

Tsai HR, Wang JH, Huang HK, Chen TL, Chen PW, Chiu CJ. Efficacy of atropine, orthokeratology, and combined atropine with orthokeratology for childhood myopia: A systematic review and network meta-analysis. J Formos Med Assoc. 2022 Dec;121(12):2490-2500. doi: 10.1016/j.jfma.2022.05.005.

Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, Twelker JD. Intervenciones para retardar la progresión de la miopía en niños. Cochrane Database Syst Rev. 2020 13 de enero;1(1):CD004916. doi: 10.1002/14651858.CD004916.pub4.

Zhao C, Cai C, Ding Q, Dai H. Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis. BMC Ophthalmol. 2020 Dec 7;20(1):478. doi: 10.1186/s12886-020-01746-w.

Vagge A, Ferro Desideri L, Nucci P, Serafino M, Giannaccare G, Traverso CE. Prevention of Progression in Myopia: A Systematic Review. Diseases. 2018; 6(4):92. https://doi.org/10.3390/diseases6040092.